Edit Symbol List
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Company Description (as filed with the SEC)
We are an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. We acquire, in-license and develop oncology product candidates. We have in-licensed and are currently developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. We submitted a new drug application, or NDA, for an oral formulation of rolapitant, to the U.S. Food and Drug Administration, or the FDA, in September 2014. If the NDA is approved by the FDA, oral rolapitant will become our first marketed product. In March 2014, we added immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc., or AnaptysBio, for the discovery and development of antibodies for several specified immuno-oncology targets. † Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, or CINV. ... More ...
Where does TSRO fit in the risk graph?
|Annual EPS Est:||$-4.79|
|Quarterly EPS Est:||-1.14|